Affiliation:
1. Department of Drugs and Medicines, Sao Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, Sao Paulo, Brazil
Abstract
Following progress in modern medicine, advances have been made in diagnosis and
treatment tools. Multifunctional nanomaterials that combine therapeutic and diagnostic functions in a
single nanostructured complex are known as ‘theranostics’. To obtain a theranostic, a single particle,
usually a nanoparticle, is manufactured to contain a therapeutic element (such as a drug) coupled
with an imaging element. There are many kinds of nanoparticles available today that can be used to
obtain theranostics, such as liposomes, cyclodextrin, conjugates and complexes, dendrimers, vesicles,
micelles, core-shell particles, microbubbles, and carbon nanotubes. Because these materials
interact with and should have effects on biological systems, their use may overcome health challenges.
Considering the novelty and importance of this subject, this review aims to present general
information about theranostics and discuss the safety and presumable toxicity of these constructs. In
addition, we describe the methodologies that can be used to assess the safety of theranostics. This
review is based on a literature search on theranostics, using the Web of Science, PubMed and Science
Direct as the main sources of information. The period of publication was not delimited due to
the scarcity of information and publications on this topic. Although many promising theranostic systems
have been investigated and may revolutionise therapy, when designing new tools, researchers
need to find alternatives to minimise their toxicity. The study of the toxicology and biocompatibility
of theranostics needs to be continued, including clinical studies, with the aim of benefitting many
patients in the future.
Funder
São Paulo Research Foundation
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering,Biotechnology
Reference100 articles.
1. Funkhouser J.; Reinventing pharma: the theranostic revolution. Curr Drug Discov 2002,2,17-19
2. Gilham I.; Theranostics: An emerging tool in drug discovery and commercialisation. Drug Discov World 2002,6,24-32
3. Mura S.; Couvreur P.; Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012,64,1394-1416
4. Butterworth K.T.; Nicol J.R.; Ghita M.; Rosa S.; Chaudhary P.; McGarry C.K.; McCarthy H.O.; Jimenez-Sanchez G.; Bazzi R.; Roux S.; Tillement O.; Coulter J.A.; Prise K.M.; Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy. Nanomedicine 2016,11,2035-2047
5. Limaye N.; Pharmacogenomics, theranostics and personalized medicine-the complexities of clinical trials: Challenges in the developing world. Appl Transl Genomics 2013,2,17-21
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献